Literature DB >> 16700948

Childhood chorea-encephalopathy associated with human parvovirus B19 infection.

Choong Yi Fong1, Carlos de Sousa.   

Abstract

An 8-year-old female presented with a distinct clinical course characterized by an acute self-limiting chorea-encephalopathy with cerebrospinal fluid (CSF)-specific oligoclonal bands. During the clinical course, genomic human parvovirus B19 DNA was detected in her serum and CSF. It was concluded that this patient represents the first published case of childhood chorea-encephalopathy associated with, and probably caused by, human parvovirus B19 infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16700948     DOI: 10.1017/S0012162206001101

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  5 in total

Review 1.  Acute encephalitis and encephalopathy associated with human parvovirus B19 infection in children.

Authors:  Toru Watanabe; Hideshi Kawashima
Journal:  World J Clin Pediatr       Date:  2015-11-08

2.  Persistent adeno-associated virus 2 and parvovirus B19 sequences in post-mortem human cerebellum.

Authors:  James K Grant; Natalie C Yin; Annette M Zaytoun; Hena Waseem; Jacqueline A Hobbs
Journal:  Cerebellum       Date:  2009-07-08       Impact factor: 3.847

3.  Treatment of Complex Regional Pain Syndrome (CRPS) using low dose naltrexone (LDN).

Authors:  Pradeep Chopra; Mark S Cooper
Journal:  J Neuroimmune Pharmacol       Date:  2013-04-02       Impact factor: 4.147

Review 4.  Neurological aspects of human parvovirus B19 infection: a systematic review.

Authors:  Faraj Barah; Sigrid Whiteside; Sonia Batista; Julie Morris
Journal:  Rev Med Virol       Date:  2014-01-24       Impact factor: 6.989

Review 5.  Neuroinflammation, neuroautoimmunity, and the co-morbidities of complex regional pain syndrome.

Authors:  Mark S Cooper; Vincent P Clark
Journal:  J Neuroimmune Pharmacol       Date:  2012-08-25       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.